Regulatory & Legal

A new heavy-lift drone can autonomously airdrop supplies into contested zones with precision, signaling a fundamental shift in military and humanitarian aid.

A bitter global patent war ends quietly. We dissect how the Amazon-InterDigital pact reveals the hidden costs of innovation and the new rules of tech engagement.

Paradisus La Perla's new WITT certification isn't just an award; it's a strategic move by Meliá to capture the booming $1.3T wellness travel market.

As John Anthony Vineyards uncorks a 20th-anniversary Cabernet, the celebration reveals a larger strategy: a quiet pivot from a boutique winery to a diverse beverage empire.

A century-old seal of trust meets a new-age disruptor. We deconstruct how HOTO's design philosophy and smart technology are redefining home cleaning.

A BMO survey reveals a stark new reality: financial stability is trumping romance, trapping some in marriage and turning partnership into a fiscal strategy.

Hyundai Bioscience offers a free drug for an untreatable Ebola strain. It's a bold humanitarian gesture, and a masterclass in strategic maneuvering.

Meta's API changes have advertisers seeing red, but a drop in reported conversions doesn't mean a drop in real-world results. Here's what it really means.

When a nation-state actor targeted Utah's water infrastructure, a Native American-owned firm didn't just survive. They built a fortress. Here's how.

Oxford Commercial Finance's milestone isn't just a number; it's a sign of a deep shift. As traditional banks step back, who is funding America's growth?

In a region hit hard by lung cancer, Tanner Health proves innovation isn't just for big cities, deploying a powerful AI to save lives in Georgia and Alabama.

A market set to triple, driven by gene-level therapies, promises a revolution for children with rare epilepsies. But can our systems deliver this hope?

Cytovance Biologics' new cell line service boasts top-tier yields. This strategic shift toward a 'one-stop-shop' model could redefine speed and cost in biopharma.

Following a controversial board purge, ousted Pangaea directors are threatening a shareholder revolt, raising critical questions about corporate oversight.

Organon's FDA nod for TOFIDENCE in critical care isn't just a clinical win. It's a calculated move to capture market share and challenge high-cost biologics.

U.S. Gold's latest move at its CK Gold project is no mere update; it's a signal of intent to redefine the project's scale and chase historical riches.

After a 60-year battle against a defunct freeway, South Pasadena is selling eight historic homes, offering a rare chance at ownership in a tight market.

Leading Edge Materials confirms a low-cost, high-purity graphite process at its Swedish mine, positioning Woxna to supply Europe's booming EV battery market.

Biotech firm Sensorion drops one gene therapy to fast-track another, aiming to cure GJB2-related hearing loss, the leading cause of genetic deafness.

Facing burnout and fearing for patient safety, 250 clinicians at Seattle's top cancer centers are unionizing, challenging the very structure of modern healthcare.